The British pharmaceutical regulator said on April 2 that it had found 30 cases of rare blood clots following vaccination with the Astrografin 2019 coronavirus disease (COVID-19) vaccine, 25 more than previously reported, although authorities still believe the benefits of the AZ vaccine far outweigh the drawbacks.
Reuters reported that the UK Medicines and Healthcare products Regulatory Agency (Medicines and Healthcare products Regulatory Agency) pointed out that the Authority did not receive the COVID-19 vaccine jointly developed by the German biotechnology company BioNTech and the US Pfizer Inc. 19 vaccine developed by the German biotech company BioNTech and Pfizer Inc.
But Authority officials said they still believe the benefits of the vaccine from British drugmaker AstraZeneca in preventing infection with COVID-19 far outweigh any possible risk of blood clots.
Some countries continue to restrict the use of the AZ vaccine, while others have resumed vaccination. Authorities are still investigating notified cases of rare and sometimes severe blood clots.
The UK Medicines and Healthcare Products Regulatory Agency said on March 18 that five rare cases of cerebral thrombosis have been reported out of 11 million doses of the vaccine.
Of the total 18.1 million doses of AZ vaccine administered, 22 cases of cerebral sinus embolism were reported and 8 other cases of thrombosis related to low blood platelets were reported, the agency said today. Cerebral venous sinus embolism is an extremely rare blood clot disease in the brain.
There were also problems with the AZ vaccine in Germany. According to reports, the Paul Ehrlich Institute (PEI), the official body responsible for approving vaccines in Germany, has reported 31 cases of blood clots caused by AZ vaccine administration, of which 9 people have died. All but two of the cases were in women between the ages of 20 and 63.
Recent Comments